CD19 chimeric antigen receptor-T cells in B-cell leukemia and lymphoma: Current status and perspectives Review
| Authors: | Mohty, M.; Gautier, J.; Malard, F.; Aljurf, M.; Bazarbachi, A.; Chabannon, C.; Kharfan-Dabaja, M. A.; Savani, B. N.; Huang, H.; Kenderian, S.; Nagler, A.; Perales, M. A. |
| Review Title: | CD19 chimeric antigen receptor-T cells in B-cell leukemia and lymphoma: Current status and perspectives |
| Abstract: | The approval of tisagenlecleucel and axicabtagene ciloleucel represents a breakthrough in the field of immune and cellular therapy for hematologic malignancies. These anti-CD19 chimeric antigen receptor-T cells (CAR) proved to be highly effective in the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) and specific histologic subtypes of B-cell non-Hodgkin lymphomas. This expert review aims to summarize the current available research evidence in this field, with a special focus on the different challenges faced by treating physicians, and we also provide future perspectives. © 2019, The Author(s), under exclusive licence to Springer Nature Limited. |
| Keywords: | cancer survival; overall survival; fludarabine; review; drug efficacy; neurotoxicity; evidence based medicine; progression free survival; cyclophosphamide; acute lymphoblastic leukemia; b cell lymphoma; nonhodgkin lymphoma; physician; large cell lymphoma; b cell leukemia; diffuse large b cell lymphoma; tocilizumab; human; priority journal; lymphocytic lymphoma; tisagenlecleucel t; chimeric antigen receptor t-cell immunotherapy; axicabtagene ciloleucel; lisocabtagene maraleucel |
| Journal Title: | Leukemia |
| Volume: | 33 |
| Issue: | 12 |
| ISSN: | 0887-6924 |
| Publisher: | Nature Publishing Group |
| Date Published: | 2019-12-01 |
| Start Page: | 2767 |
| End Page: | 2778 |
| Language: | English |
| DOI: | 10.1038/s41375-019-0615-5 |
| PUBMED: | 31690821 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Review -- Export Date: 2 January 2020 -- Source: Scopus |
